Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 2Phase 1/2 1

Status

Unknown 7Terminated 2Completed 2

Sponsor Class

INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 2Breast 2Dermatologic 1

Conditions

Breast Neoplasms 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Melanoma 1Carcinoma, Transitional Cell 1Adenocarcinoma of the Stomach 1

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 119sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89Leucovorin 86pembrolizumab 85toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × Unknown × tesetaxel × Clear all
NCT01221870 2012-07-24

Tesetaxel as First-line Therapy for Metastatic Breast Cancer

Genta Incorporated

Phase 2 Unknown
81 enrolled
Breast

Breast Neoplasms

NCT01296243 2012-07-24

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Genta Incorporated

Phase 2 Unknown
57 enrolled
Genitourinary

Prostatic Neoplasms

NCT01573468 2012-07-24

TESEGAST

Genta Incorporated

Phase 2 Unknown
580 enrolled
Gastrointestinal

Stomach Neoplasms

NCT01215877 2012-07-11

Tesetaxel for Previously Treated Patients With Bladder Cancer

Genta Incorporated

Phase 2 Unknown
33 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01609127 2012-06-01

Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

Genta Incorporated

Phase 2 Unknown
213 enrolled
Breast

Breast Neoplasms

NCT01095120 2012-03-15

Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

Genta Incorporated

Phase 2 Unknown
27 enrolled
Gastrointestinal

Adenocarcinoma of the Stomach

NCT01092585 2011-11-08

Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

Genta Incorporated

Phase 2 Unknown
27 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡